Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
361.62B
Market cap361.62B
Price-Earnings ratio
150.07
Price-Earnings ratio150.07
Dividend yield
2.31%
Dividend yield2.31%
Average volume
8.58M
Average volume8.58M
High today
$147.91
High today$147.91
Low today
$145.24
Low today$145.24
Open price
$147.31
Open price$147.31
Volume
1.93M
Volume1.93M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$90.90
52 Week low$90.90

Stock Snapshot

With a market cap of 361.62B, Merck(MRK) trades at $146.69. The stock has a price-to-earnings ratio of 150.07 and currently yields dividends of 2.31%.

As of 2026-11-13, Merck(MRK) stock has fluctuated between $145.24 and $147.91. The current price stands at $146.69, placing the stock +1.0% above today's low and -0.8% off the high.

The Merck(MRK)'s current trading volume is 1.93M, compared to an average daily volume of 8.58M.

During the past year, Merck(MRK) stock moved between $90.90 at its lowest and $156.92 at its peak.

During the past year, Merck(MRK) stock moved between $90.90 at its lowest and $156.92 at its peak.

MRK News

Investing.com 6h
EU committee backs Merck’s Welireg-lenvatinib for kidney cancer - Investing.com

...

EU committee backs Merck’s Welireg-lenvatinib for kidney cancer - Investing.com
TipRanks 6h
Merck announces European CHMP recommends approval of Enflonsia

Merck (MRK), known as MSD outside of the U.S. and Canada, announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines...

TipRanks 6h
Merck reports European CHMP recommends approval of Welireg

Merck (MRK), known as MSD outside of the U.S. and Canada, announced the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, ado...

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
26.7%
Sell
3.3%

More MRK News

TipRanks 1d
Moderna says Marlborough expected to become global supply site for intismeran

The company said, “Manufacturing is a core component of Moderna’s (MRNA) integrated mRNA platform, supporting commercial vaccine supply, strategic partnerships...

TipRanks 1d
Surrozen price target raised to $80 from $42 at Guggenheim

Guggenheim raised the firm’s price target on Surrozen (SRZN) to $80 from $42 and keeps a Buy rating on the shares. Following Merck’s (MRK) full disclosure of Re...

24/7 Wall St. 2d
Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year
Benzinga 2d
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead S...

EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
Simply Wall St 3d
Merck Stock May Be 38% Undervalued As Liver Trial News Lands

has delivered a strong multi‑year share price run, and with the stock last closing at US$148.76, the live question is whether that level is supported by the cas...

Merck Stock May Be 38% Undervalued As Liver Trial News Lands
Simply Wall St 6d
Merck Could Be 8% Undervalued Following Strong Phase 3 Cancer Data

Merck (MRK) is back in focus after a run of late October oncology readouts, including Phase 3 wins for KEYTRUDA and sacituzumab tirumotecan in endometrial cance...

Merck Could Be 8% Undervalued Following Strong Phase 3 Cancer Data

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.